Nonetheless, although SNPs in the human HER2 gene have been associated with the susceptibility, clinical course, and response to treatment of breast cancer disease [37,38,39], the knowledge regarding the influence of HER2 SNPs on clinicopathological features and prognosis of CMT is still incomplete. The gene discussed is ERBB2; the disease is breast carcinoma.